From: Recovery of physical function in lung transplant recipients with sarcopenia
Total (n = 55) | Sarcopenia (n = 19) | Non-sarcopenia (n = 36) | P-value | |
---|---|---|---|---|
Patients' characteristics | ||||
Age at LTX, median (IQR) | 44 (33–50) | 45 (34–50) | 44 (33–50) | 0.878 |
Female, n (%) | 29 (52.7%) | 12 (63.2%) | 17 (47.2%) | 0.260 |
LTX procedure, n (%) | 0.529 | |||
Single | 27 (49.1%) | 8 (42.1%) | 19 (52.8%) | |
Double | 27 (49.1%) | 11 (57.9%) | 17 (47.2%) | |
Living-donor | 1 (1.8%) | 1 (5.3%) | 0 (0.0%) | |
LTX indication, n (%) | 0.550 | |||
Pulmonary Vascular Disease | 10 (18.2%) | 5 (26.3%) | 5 (13.9%) | |
Restrictive Lung Disease | 14 (25.5%) | 4 (21.1%) | 10 (27.8%) | |
Obstructive Lung Disease | 20 (36.4%) | 8 (42.1%) | 12 (33.3%) | |
Suppurative Lung Disease | 8 (14.5%) | 1 (5.3%) | 7 (19.4%) | |
Others | 3 (5.4%) | 1 (5.3%) | 2 (5.6%) | |
Pre- and intra-operative condition | ||||
6MWD (m), median (IQR) | 318 (216–373) | 316 (221–387) | 318 (204–369) | 0.524 |
Body-mass index (kg/m2), median (IQR) | 18.0 (17.0–22.0) | 18.0 (17.0–24.0) | 18.5 (16.3–21.0) | 0.815 |
On supplemental oxygen, n (%) | 49 (89.1%) | 17 (89.5%) | 32 (88.9%) | 0.999 |
Diabetes, n (%) | 4 (7.3%) | 3 (15.8%) | 1 (2.8%) | 0.077 |
Connective tissue disease, n (%) | 9 (16.4%) | 3 (15.8%) | 6 (16.7%) | 0.933 |
Chronic kidney disease, n (%) | 2 (3.6%) | 2 (10.5%) | 0 (0.0%) | 0.047 |
Waiting time (month), median (IQR) | 26 (18–36) | 26 (19–37) | 26 (17–35) | 0.559 |
Donor age, median (IQR) | 43 (31–47) | 43 (26–49) | 42.5 (31.5–51) | 0.411 |
Ischemic time (min) | 535 (452–697) | 483 (403–717) | 555 (456–694) | 0.323 |
CMV mismatch (D + /R-), n (%) | 10 (18.2%) | 5 (26.3%) | 5 (13.9%) | 0.288 |
Post-operative condition and complications | ||||
Primary graft dysfunction, n (%) | 45 (81.8%) | 17 (89.5%) | 28 (77.8%) | 0.465 |
Requirement of tracheostomy, n (%) | 28 (50.9%) | 13 (68.4%) | 15 (42.7%) | 0.089 |
Continuous renal replacement therapy, n (%) | 9 (16.4%) | 5 (26.3%) | 4 (11.1%) | 0.249 |
Invasive mechanical ventilation (day), median (IQR) | 12 (4–29) | 18 (5–60) | 7 (4–21) | 0.052 |
ICU stay (day), median (IQR) | 19 (9–39) | 29 (16–68) | 15 (7–31) | 0.024 |
Hospital stay (day), median (IQR) | 85 (64–114) | 98 (64–170) | 81 (62–95) | 0.060 |
Acute allograft rejection, n (%) | 9 (16.4%) | 3 (15.8%) | 6 (16.7%) | 0.999 |
ESM-CSA ( cm2/m2), median (IQR) | 15.7 (14.0–17.9) | 13.6 (12.6–14.9) | 17.3 (14.8–18.8) | < .0001 |
%predicted hand-grip strength, median (IQR) | 54.0 (43.5–62.0) | 39.0 (28.0–49.0) | 58.0 (52.0–67.0) | < .0001 |
Hand-grip strength (kg), median (IQR) | 20.0 (15.0–28.0) | 14.0 (11.8–17.3) | 24.0 (20.0–29.0) | < .0001 |
%predicted 6MWD, median (IQR) | 65.0 (48.0–79.0) | 39.0 (31.0–64.0) | 74.5 (62.0–81.8) | < .0001 |
6MWD (m), median (IQR) | 447 (309–483) | 309 (195–399) | 476 (426–519) | < .0001 |
Body-mass index (kg/m2), median (IQR) | 17.0 (15.0–21.0) | 17.0 (15.0–22.0) | 17.0 (16.0–20.0) | 0.891 |
FEV1 (L), median (IQR) | 1.56 (1.30–1.95) | 1.36 (1.13–1.56) | 1.78 (1.37–2.02) | 0.013 |
Follow-up duration in months, median (IQR) | 48 (26–70) | 43 (22–76) | 49 (27–67) | 0.571 |